November 29, 2016 - By olga
Thomas Wegman, the President of Biospecifics Technologies Corp, unloaded 10,000 shares of the company, that are worth around $480,832 USD, at an average $48.1 of a share. Now, he possess 949,973 shares or 12.65% of the Company’s market cap (share price times the number of shares outstanding).
Insitutional Activity: The institutional sentiment decreased to 1.42 in 2016 Q2. Its down 1.01, from 2.43 in 2016Q1. The ratio dropped, as 7 funds sold all BioSpecifics Technologies Corp. shares owned while 14 reduced positions. 8 funds bought stakes while 43 increased positions. They now own 3.62 million shares or 3.75% more from 3.49 million shares in 2016Q1.
Dimensional Fund Limited Partnership holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 178,251 shares. Strs Ohio has 0% invested in the company for 9,800 shares. Putnam Investments Ltd Liability Corporation last reported 54,450 shares in the company. Paradigm Asset Mngmt Ltd Liability Com has 450 shares for 0% of their US portfolio. Bancorporation Of New York Mellon last reported 0% of its portfolio in the stock. Goldman Sachs reported 36,472 shares or 0% of all its holdings. Pnc Financial Svcs Grp Incorporated has invested 0.01% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Mutual Of America Mgmt Lc has invested 0.05% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Geneva Advsr Limited Com has 14,072 shares for 0.01% of their US portfolio. Us Bancshares De last reported 0% of its portfolio in the stock. Dafna Cap Mngmt Llc reported 39,704 shares or 1.26% of all its holdings. Royal Natl Bank Of Canada has 0% invested in the company for 50 shares. Cornerstone Capital Management Ltd Company holds 3,600 shares or 0% of its portfolio. Invesco holds 0% or 51,435 shares in its portfolio. American has invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC).
Insider Transactions: Since August 23, 2016, the stock had 0 buys, and 7 selling transactions for $1.53 million net activity. On Thursday, September 15 the insider Wegman Toby sold $127,751. 3,100 shares were sold by Wegman Thomas, worth $127,751.
The stock increased 5.06% or $2.4 on November 29, hitting $49.85. About 82,988 shares traded hands or 162.37% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 33.14% since April 26, 2016 and is uptrending. It has outperformed by 27.88% the S&P500.
BioSpecifics Technologies Corp. is a biopharmaceutical company. The company has a market cap of $338.18 million. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. It has a 32.67 P/E ratio. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development.
According to Zacks Investment Research, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals.”
Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on March, 13. They expect $0.38 earnings per share, up 5.56% or $0.02 from last year’s $0.36 per share. BSTC’s profit will be $2.58M for 32.80 P/E if the $0.38 EPS becomes a reality. After $0.42 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.
More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Prnewswire.com which released: “BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results” on November 09, 2016, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of ..” published on November 17, 2016, Quotes.Wsj.com published: “News BioSpecifics Technologies Corp.BSTC” on February 12, 2011. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Prnewswire.com and their article: “BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results ..” published on November 02, 2016 as well as Seekingalpha.com‘s news article titled: “BioSpecifics Technologies Corp. Has A 6-Year Expiration Date” with publication date: August 03, 2016.
BioSpecifics Technologies Corp. (BioSpecifics), incorporated on November 1, 1990, is a biopharmaceutical company. The Firm is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Firm has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. The Company’s injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.